Adding a PD-1 inhibitor to standard of care improved disease-free survival (DFS) in stage III soft-tissue sarcoma of the ...

Efti + KEYTRUDA combo shows strong efficacy for NSCLC patients in Immutep's phase 1 study. Read why IMMP stock may see upside ...

Addition of the immunotherapy drug pembrolizumab to standard of care for patients with advanced soft tissue sarcoma of the ...

Immutep (IMMP) has released an update. Immutep Limited has announced promising results from its Phase II trial of eftilagimod alpha, combined ...

Media ReleaseEfti in combination with pembrolizumab and radiotherapy demonstrates significant efficacy in the neoadjuvant setting in patients ...

Pembrolizumab, an immunotherapy medication, significantly enhanced disease-free survival when added to the standard of care ...

PITTSBURGH — Addition of the immunotherapy drug pembrolizumab to standard of care for patients with advanced soft tissue ...

Adaptimmune’s Phase II IGNYTE-ESO trial investigating experimental T cell therapy lete-cel has achieved its primary endpoint.

The FDA has given accelerated approval to a groundbreaking T cell-based therapy from Adaptimmune for synovial sarcoma, becoming the first new treatment for the rare soft tissue cancer in mo ...

Ms Deanne Miller (General Counsel, Company Secretary, Chief Op. Officer) ...

INVINCIBLE-3 Study: a Phase 3 open-label, randomized study testing INT230-6 as monotherapy compared to the SOC drugs in second and third line treatment for certain soft tissue sarcoma subtypes. The ...

Addition of the immunotherapy drug pembrolizumab to standard of care for patients with advanced soft tissue sarcoma of the ...